Bepogen1.5%

Bepogen ophthalmic solution is an FDA-approved topical antihistamine used for the treatment of ocular itching associated with allergic conjunctivitis.

• Established/approved use: Relief of itching due to allergic conjunctivitis (seasonal/perennial allergic conjunctivitis) in patients 2 years of age and older, applied directly to the eye.
• Other-market use (oral formulation): In some countries, an oral tablet form of Bepogen is used by physicians for allergic rhinitis and chronic urticaria/pruritus, based on local regulatory approval; this oral form is not FDA-approved and is not marketed in all countries.

Bepogen should only be used for the indication and dosage form prescribed by a physician.

Each mL of the ophthalmic solution contains Bepotastine Besilate 15 mg (1.5% w/v) as the active ingredient.

Inactive ingredients typically include benzalkonium chloride (preservative), sodium chloride, and other tonicity/pH-adjusting agents in purified water. Oral formulations of Bepotastine Besilate, where marketed, contain the same active moiety in tablet form with standard pharmaceutical excipients.

Bepogen is a second-generation, selective histamine H1-receptor antagonist that also has mast-cell-stabilizing activity. It is most widely used as a 1.5% ophthalmic solution for allergic conjunctivitis, where it directly blocks H1 receptors in the conjunctival tissue to relieve itching. In some countries an oral form is also available for systemic allergic conditions.

Bepogen belongs to the class of second-generation H1-antihistamines with additional mast cell-stabilizing properties. In its ophthalmic form, it is classified as a topical ocular anti-allergic/anti-histaminic agent.

Mechanism of Action

Bepotastine Besilate is a direct histamine H1-receptor antagonist. By selectively blocking H1 receptors on conjunctival nerve endings and blood vessels, it reduces itching, redness, and vasodilation triggered by histamine release from mast cells. It also has secondary mast-cell-stabilizing activity that inhibits further histamine release.

Pharmacokinetics (Ophthalmic Use)

• Absorption: Systemic absorption is minimal after topical ocular dosing; peak plasma levels occur within 1-2 hours and are very low.
• Protein binding: Approximately 55%, independent of concentration.
• Metabolism: Undergoes minimal hepatic (CYP450) metabolism, which explains its low potential for drug interactions.
• Excretion: Primarily excreted unchanged in urine (roughly 75-90%).

• For ophthalmic use only; do not inject or take the eye drop formulation by mouth.
• Wash hands before use. Tilt the head back, pull down the lower eyelid, and instill one drop into the pocket formed.
• Avoid touching the dropper tip to the eye, fingers, or any surface to prevent contamination.
• Remove contact lenses before instilling Bepogen; lenses may be reinserted 10 minutes after dosing.
• If using other eye medications, space them at least 5-10 minutes apart from Bepogen.
• If an oral tablet form is prescribed, take it exactly as directed by the physician, with or without food as instructed.

Bepogen undergoes minimal hepatic metabolism and has low systemic absorption when used ophthalmically, resulting in a low potential for clinically significant drug interactions. No well-established, clinically significant drug-drug interactions have been documented for the ophthalmic solution.

As a general precaution, other topical ophthalmic products should be administered at least several minutes apart from Bepogen to avoid dilution or washout of either medication. Patients using an oral formulation of Bepogen should inform their physician of all other medicines used, particularly other antihistamines or CNS-sedating drugs, since additive drowsiness is theoretically possible.

Most side effects of Bepogen ophthalmic solution are mild and localized to the eye or mouth.

Common

• Mild, transient taste disturbance (bad/unusual taste) immediately after instillation
• Eye irritation or a mild burning/stinging sensation
• Headache
• Nasopharyngitis (cold-like symptoms)

Rare/Post-marketing

• Hypersensitivity reactions such as itching, skin rash, or swelling of the lips, tongue, or throat

Patients should seek medical attention if signs of an allergic reaction occur (see Contraindications).

Pregnancy

Adequate and well-controlled studies of Bepogen in pregnant women are lacking. Animal reproduction studies have not shown adverse effects on the fetus at clinically relevant exposures, but human data are limited. Bepogen should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation

It is not known whether Bepogen is excreted in human breast milk in clinically significant amounts. Animal data suggest passage of drug-related material into milk. Caution is advised, and a physician should be consulted before using Bepogen while breastfeeding.

• For ophthalmic use only; not for injection or oral consumption unless a specific oral product is prescribed.
• Avoid touching the dropper tip to the eye or any surface to prevent contamination of the solution.
• Bepogen should not be used to treat contact lens-related irritation.
• Remove contact lenses prior to instillation; a preservative in the solution may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes after dosing.
• Vision may be temporarily blurred after instillation; do not drive or operate machinery until vision clears.
• Discontinue and seek medical advice if hypersensitivity reactions occur (see Contraindications).

Ophthalmic overdose of Bepogen is unlikely to cause systemic toxicity due to minimal systemic absorption; excess solution should be flushed from the eye with lukewarm water. If an oral formulation is accidentally ingested in excess, or if any concerning symptoms occur after any form of Bepogen use, seek immediate medical attention or contact a poison control center rather than attempting home treatment.

Store Bepogen ophthalmic solution between 15°C and 25°C (59°F to 77°F), protected from light. Do not freeze. Keep the bottle tightly closed when not in use, and keep out of reach of children.

Pediatric Use

Safety and efficacy of Bepogen ophthalmic solution have been established in children 2 years of age and older; safety and efficacy in children under 2 years have not been established.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients using Bepogen ophthalmic solution.

Renal/Hepatic Impairment

No specific dose adjustment is required for the ophthalmic solution due to minimal systemic absorption; data in significant renal or hepatic impairment for any oral form are limited, and such patients should be monitored closely by their physician.

Bepogen is generally used for as long as allergic symptoms persist, such as through a seasonal allergy period, under a physician's guidance. If symptoms do not improve within a few days of regular use, or if they worsen, the patient should consult their physician to reassess the diagnosis and treatment plan.

Second-generation H1-antihistamine with mast cell-stabilizing activity; topical ophthalmic anti-allergic agent (Bepotastine Besilate).

Bepotastine Besilate selectively and competitively blocks histamine H1 receptors, preventing histamine from binding and triggering itching, vasodilation, and increased vascular permeability in ocular (and, with oral use, nasal/dermal) tissue. It additionally stabilizes mast cell membranes, reducing further release of histamine and other inflammatory mediators, which contributes to its anti-allergic effect.

Bepogen ophthalmic solution is approved for use in children 2 years of age and older at the same dose as adults (1 drop in the affected eye(s) twice daily). Safety and efficacy in children younger than 2 years have not been established, and the ophthalmic solution should not be used in this age group unless specifically directed by a pediatrician. Any oral formulation of Bepogen should be used in children only under close pediatric medical supervision, following local prescribing guidance.